Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Medical Research and Opinion|November 27, 2012
Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy useWanying Li, Eric H Sasso, Daniel Emerling, et al.
Arthritis Care & Research|August 31, 2023
Development of an Interactive Tool to Support Shared Decision-Making in Rheumatoid Arthritis: Treatment Attribute PreferenceJeffrey R Curtis, Kerri Ford, Stefano Fiore, et al.
Rheumatology (Oxford, England)|April 17, 2015
Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritisKaleb Michaud, Vibeke Strand, Nancy A Shadick, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 1, 2023
Improvement or Worsening of Disease Activity After Switch to Sarilumab in Patients With Rheumatoid Arthritis With a Partial Response to AdalimumabJeffrey R Curtis, Daniel Aletaha, Gerd Burmester, et al.
Arthritis Research & Therapy|December 21, 2022
The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registryAnthony S Padula, Dimitrios A Pappas, Stefano Fiore, et al.
Rheumatology (Oxford, England)|November 22, 2022
Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumabErnest Choy, Vivian Bykerk, Yvonne C Lee, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 31, 2023
Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA RegistryJeffrey R Curtis, Stefano Fiore, Kerri Ford, et al.
Rheumatology and Therapy|June 22, 2023
Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE RegistryJeffrey R Curtis, Huifeng Yun, Lang Chen, et al.
Rheumatology and Therapy|October 31, 2023
Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational StudyAnisha B Dua, Kerri Ford, Stefano Fiore, et al.
Clinical Rheumatology|April 15, 2023
Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA RegistryAnthony Sebba, Clifton O Bingham, Vivian P Bykerk, et al.
Pageof 2